Clinical Trials · NCT06312670
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Pedro Barata, MD, MSc
- Enrollment
- 13
- Start date
- May 2024
- Locations
- 2 sites, United States
- Primary endpoint
- Biochemical response rate